Drug Profile
XCE 853
Alternative Names: XCE-853Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Oregon Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Isomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for preclinical development in Ovarian-cancer in France (PO)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Pancreatic-cancer in France (PO)
- 01 Apr 2017 Pharmacodynamics and pharmacokinetics data from a preclinical studies presented at the 108th Annual Meeting of the American Association for Cancer Research